Owens & Minor (OMI)
(Delayed Data from NYSE)
$16.48 USD
+1.17 (7.64%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.48 USD
+1.17 (7.64%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Bruker (BRKR) to Improve Spatial Biology With New Launch
by Zacks Equity Research
Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.
Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform
by Zacks Equity Research
The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.
McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
by Zacks Equity Research
Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
Here's Why You Should Hold on to STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.
Medtronic (MDT) Reports First Procedure in Europe With Hugo RAS
by Zacks Equity Research
Medtronic's (MDT) Hugo RAS system was utilized to perform robotic prostatectomy at OLV Hospital in Aalst, Belgium.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
by Zacks Equity Research
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Medtronic (MDT) Undertakes Investment to Advance STEM Education
by Zacks Equity Research
The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.
Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What Makes Owens & Minor (OMI) a Good Fit for "Trend Investing"
by Zacks Equity Research
Owens & Minor (OMI) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Company News for Jan 11, 2022
by Zacks Equity Research
Companies in The News Are: CMC,AZZ,ZNGA,TTWO,APR,OMI
All You Need to Know About Owens & Minor (OMI) Rating Upgrade to Buy
by Zacks Equity Research
Owens & Minor (OMI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.